Top Markets
#1 Ontology Gas Ontology Gas +40.10%
#2 Verus Coin Verus Coin +22.50%
#3 EXOD EXOD +22.08%
#4 Status Status +19.99%
#5 Geodnet Geodnet +14.90%
#6 ETHGas ETHGas +13.90%
#7 The Black Bull The Black Bull +12.16%
#8 Fake World Assets Fake World Assets +11.14%
#9 Curve DAO Curve DAO +10.88%
#10 Pons Pons +10.54%
Coin of the day
Ontology Gas Ontology Gas
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rang in Aktien #25521
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Aktienkurs
$9.81
Zuletzt synchronisiert: 2025-03-18
Marktkapitalisierung
$48.68M
Veränderung (1 Tag)
1.55%
Veränderung (1 Jahr)
0.00%
Land
US
Handel AlloVir, Inc. (ALVR)

Kategorie

Healthcare
Gewinn für AlloVir, Inc. (ALVR)
Gewinn im Jun 2026 TTM: $-54.46M
Laut den aktuellen Finanzberichten von AlloVir, Inc. betragen die aktuellen Gewinne des Unternehmens $-54.46M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-190.54M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-168.98M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von AlloVir, Inc. von 2018 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-54.46M -7.33%
2024 $-58.77M -69.16%
2023 $-190.54M 12.76%
2022 $-168.98M -1.16%
2021 $-170.96M 144.98%
2020 $-69.78M 192.73%
2019 $-23.84M 881.03%
2018 $-2.43M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -9,786.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,681.87%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -3,064.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 5,568.48%
US